Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News